ISOREA AD Risk Detection Kit is the solution to enable detecting AD when it is possible to prevent the disease progression


Our Publications

1. Yang, H.; Fung, Y. M.; Zubarev, A. R.; Zubarev, R. A.  Toward proteome-scale identification and quantification of isoaspartyl residues in biological samples. J. Proteome Res. 2009, 8, 4615–4621. https://doi.org/10.1021/pr900428m  

2. Yang, H.; Zubarev, R. A. Mass spectrometric analysis of asparagine deamidation and aspartate isomerization in polypeptides, Electrophoresis, 2010, 31, 764–1772. https://doi.org/10.1002/elps.201000027

3. Yang, H.; Lyutvinskiy, Y.; Soininen, H.; Zubarev, R. A. Alzheimer’s disease and mild cognitive impairment are associated with elevated levels of isoaspartyl residues in blood plasma proteins, J. Alzheimer’s Disease, 2011, 27, 113-118. https://doi.org/10.3233/JAD-2011-110626

4. Yang, H.; Lowenson, J.; Clarke, S.; Zubarev, R. A. Brain proteomics supports the role of glutamate metabolism and suggests other metabolic alterations in protein L-isoaspartyl methyltransferase (PIMT)-knockout mice,  J Proteome Res, 2013, 12, 4566−4576. https://doi.org/10.1021/pr400688r

5. Antila, K.; Lotjonen, J.; Thurfjell, L.; Laine, J.; Massimini, M.; Rueckert, D.; Zubarev, R. A.; Oresic, M.; van Gils, M.; Mattila, J.; Simonsen, A. H.; Waldemar, G.; Soininen, H. The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease, Interface Focus, 2013, 3, Article Number: 20120072. https://doi.org/10.1098/rsfs.2012.0072

6. Lundström, S. L.; Yang, H.; Lyutvinskiy, Y.; Rutishauser, D.; Herukka, S.-K.;  Soininen, H.; Zubarev, R. A. IgG blood plasma Fc glycans are significantly altered in Alzheimer’s disease and progressive mild cognitive impairment, J Alzheimer’s Disease, 2014, 38, 567-579. https://doi.org/10.3233/JAD-131088

7. Yang, H.; Lyutvinskiy, Y.; Herukka, S.-K.; Soininen, H.; Rutishauser, D.; Zubarev, R. A.  Prognostic polypeptide blood plasma biomarkers of Alzheimer’s disease progression, J Alzheimer’s Disease, 2014, 40, 659-66. https://doi.org/10.3233/JAD-132102

8. Wang, J.; Lundström, S. L.; Seelow, S.; Rodin, S.; Meng, Z.; Astorga-Wells, J.; Jia, Q.;  Zubarev, R. A.  First Immunoassay for Measuring Isoaspartate in Human Serum Albumin, Molecules 2021, 26, 6709; https://doi.org/10.3390/molecules26216709.

9. Wang, J.; Guo, C.; Meng, Z.; Zwan, M. D.; Chen, X.; Seelow, S.; Lundström, S. L.; Rodin, S.; Teunissen, C. E.; Zubarev, R. A. Testing the link between isoaspartate and Alzheimer's disease etiology, Alzheimer’s & Dement. 2022, PMID: 35924765. https://doi.org/10.1002/alz.12735

10. Wang, J.; Zhang, Y.-R.; Shen, X.-N.; Han, J.; Cui, M.; Tan, L.; Dong, Q.; Zubarev, R. A.*; Yu, J.-T. Deamidation-related blood biomarkers show promise for early diagnostics of neurodegeneration, Biomarker Research, 2022, 10, 1-10. https://doi.org/10.1186/s40364-022-00435-8

11. Wang, J.; Mukherjee, S.; Zubarev, R. A. Isoaspartate and neurodegeneration, Aging 2022, https://doi.org/10.18632/aging.204420

12. Wang, J.; Lundström, S. L.; Lu, W.; Huang, Y.; Rodin, S.; Zubarev, R. A. SpotLight proteomics identifies variable sequences of blood antibodies specific against deamidated human serum albumin, Mol Cell Proteom 2023, 22(7), 100589; https://doi.org/10.1016/j.mcpro.2023.100589